Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients
Launched by BARZILAI MEDICAL CENTER · Jun 7, 2018
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called metoclopramide to help women who have a poor response to in vitro fertilization (IVF). Poor ovarian response means that a woman's ovaries do not produce enough eggs during the treatment. The researchers believe that metoclopramide, which is usually used to relieve nausea, might help improve the response of the ovaries to fertility medications, potentially leading to better egg retrieval outcomes.
To participate in this trial, women must be between the ages of 18 and 43 and meet specific criteria indicating they have a poor ovarian response, based on established guidelines. However, women who are allergic to metoclopramide, have certain hormone-related conditions, or are taking specific medications that affect dopamine will not be eligible. Participants in the trial can expect to receive the medication while being closely monitored, and the study aims to find out if this treatment can lead to more successful IVF results for those with challenging ovarian responses.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Poor response according to "Bologna criteria"
- Exclusion Criteria:
- • Allergy to metoclopramide
- • Prolactinemia
- • Women treated with dopamine agonists
About Barzilai Medical Center
Barzilai Medical Center is a leading healthcare institution located in Ashkelon, Israel, renowned for its commitment to advancing medical research and patient care. As a prominent clinical trial sponsor, Barzilai Medical Center focuses on innovative treatments and therapies across various medical disciplines, collaborating with a multidisciplinary team of healthcare professionals and researchers. The center is dedicated to maintaining the highest standards of ethical practices and regulatory compliance, ensuring the safety and well-being of participants while contributing to the global body of medical knowledge. Through its robust clinical trial infrastructure, Barzilai Medical Center aims to facilitate groundbreaking research that enhances patient outcomes and fosters the development of new therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ashkelon, Ashkelon District, Israel
Patients applied
Trial Officials
Leon Grin, MD
Principal Investigator
Barzilai Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials